The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS: SocGen Upgrades BT To Buy From Hold

Fri, 16th Jan 2015 09:36

LONDON (Alliance News) - The following UK shares received analyst recommendations Friday morning and Thursday afternoon:
----------
FTSE 100
----------
SOCGEN RAISES BT GROUP TO 'BUY' ('HOLD') - PRICE TARGET 480 (245) PENCE
----------
NUMIS CUTS RANDGOLD RESOURCES TO 'HOLD' ('BUY') - TARGET 5200 (4900) PENCE
----------
NUMIS CUTS ANTOFAGASTA TO 'REDUCE' ('HOLD') - TARGET 600 (700) PENCE
----------
S&P CAPITAL IQ RAISES ASSOCIATED BRITISH FOODS PRICE TARGET TO 2500 (2250) PENCE; LEAVES AT 'STRONG SELL'
----------
GOLDMAN CUTS BRITISH AMERICAN TOBACCO PRICE TARGET TO 3142 (3150) PENCE - 'SELL'
----------
GOLDMAN CUTS DIAGEO PRICE TARGET TO 1865 (1930) PENCE - 'NEUTRAL'
----------
CREDIT SUISSE RAISES INTERNATIONAL AIRLINES GROUP PRICE TARGET TO 678 (654) PENCE - 'OUTPERFORM'
----------
TRADERS: NOMURA CUTS PRICE TARGET BRITISH AMERICAN TOBACCO TO 2870 (4060) PENCE
----------
TRADERS: NOMURA RAISES IMPERIAL TOBACCO PRICE TARGET TO 2510 (2490) PENCE
----------
MORGAN STANLEY RAISES IMPERIAL TOBACCO PRICE TARGET TO 3250 (2680) PENCE - 'OVERWEIGHT'
----------
TRADERS: NOMURA RAISES EXPERIAN PRICE TARGET TO 1215 (1200) PENCE
----------
BARCLAYS CUTS SHIRE TO 'EQUAL WEIGHT' ('OVERWEIGHT') - TARGET 5000 (4535) PENCE
----------
BARCLAYS CUTS ASTRAZENECA TO 'UNDERWEIGHT' ('EQUAL WEIGHT')
----------
BARCLAYS CUTS ASTRAZENECA PRICE TARGET TO 4600 (4400) PENCE
----------
BARCLAYS RAISES GLAXOSMITHKLINE PRICE TARGET TO 1700 (1600) PENCE - 'OVERWEIGHT'
----------
BARCLAYS CUTS TULLOW OIL PRICE TARGET TO 550 (600) PENCE - 'OVERWEIGHT'
----------
TRADERS: INVESTEC RAISES RBS TO 'HOLD' ('SELL')
----------
BARCLAYS RAISES BARRATT DEVELOPMENTS TARGET TO 507.3 (501.2) P - 'OVERWEIGHT'
----------
GOLDMAN RAISES BARRATT DEVELOPMENTS PRICE TARGET TO 502 (500) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES SABMILLER PRICE TARGET TO 3900 (3850) PENCE - 'BUY'
----------
FTSE 250
----------
SHORE CAPITAL CUTS PROVIDENT FINANCIAL TO 'HOLD' ('BUY') - TARGET 2350 PENCE
----------
SOCGEN RAISES HOME RETAIL PRICE TARGET TO 162 (156) PENCE - 'SELL'
----------
SOCGEN INITIATES TALK TALK TELECOM WITH 'HOLD' - TARGET 320 PENCE
----------
GOLDMAN SACHS RAISES TALK TALK TELECOM TO 'BUY' ('NEUTRAL') - TARGET 520.0 (474.4) PENCE
----------
BARCLAYS CUTS COUNTRYWIDE TO 'EQUAL WEIGHT' ('OVERWEIGHT')
----------
BARCLAYS CUTS COUNTRYWIDE PRICE TARGET TO 488.5 (524.8) PENCE
----------
BARCLAYS CUTS AFREN PRICE TARGET TO 28 (50) PENCE - 'UNDERWEIGHT'
----------
Investec Raises JD Sports Fashion Price Target To 610P, Keeps At Buy
----------
Cantor Fitzgerald Raises JD Sports Fashion Target To 550P, Keeps Buy
----------
GOLDMAN CUTS BOVIS HOMES PRICE TARGET TO 1177 (1214) PENCE - 'BUY'
----------
GOLDMAN CUTS BRITVIC PRICE TARGET TO 820 (830) PENCE - 'BUY'
----------
GOLDMAN RAISES ICAP PRICE TARGET TO 455 (395) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES JUST EAT PRICE TARGET TO 425 (400) PENCE - 'BUY'
----------
GOLDMAN CUTS PZ CUSSONS PRICE TARGET TO 375 (415) PENCE - 'BUY'
----------
MAIN MARKET AND AIM
----------
Numis Cuts MyCelx To Add From Buy, Price Target To 207P From 400P
----------
NUMIS CUTS MINERA IRL PRICE TARGET TO 10 (15) PENCE - 'BUY'
----------
NUMIS CUTS POLAR CAPITAL PRICE TARGET TO 420 (430) PENCE - 'HOLD'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.